相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Iruplinalkib (WX-0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Yingying Yang et al.
INVESTIGATIONAL NEW DRUGS (2023)
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Elizabeth R. Tucker et al.
CLINICAL CANCER RESEARCH (2023)
SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells
Ping Liu et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2022)
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma
Margret Merino et al.
PEDIATRIC BLOOD & CANCER (2022)
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements
Yuxiang Ma et al.
EUROPEAN JOURNAL OF CANCER (2022)
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study
Puyuan Xing et al.
BMC MEDICINE (2022)
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer
Mohammad Jahanzeb et al.
CLINICAL LUNG CANCER (2021)
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC
Elisa De Carlo et al.
Journal of Thoracic Oncology (2021)
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Brion W. Murray et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors
Shuai Wang et al.
CHINESE CHEMICAL LETTERS (2020)
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth
Jungjoong Hwang et al.
INVESTIGATIONAL NEW DRUGS (2020)
A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).
Yuxiang Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.
Yong Fang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib: First Global Approval
Zaina T. Al-Salama et al.
DRUGS (2019)
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn et al.
CLINICAL CANCER RESEARCH (2018)
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Chengwei Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Chelsea E. Powell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation
Han Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis
Niki Karachaliou et al.
EBIOMEDICINE (2018)
ALK in Neuroblastoma: Biological and Therapeutic Implications
Ricky M. Trigg et al.
CANCERS (2018)
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Chung Hyo Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
Holly L. Pacenta et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib
Sulman Basit et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
Joshua K. Sabari et al.
ONCOTARGETS AND THERAPY (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation
Peichen Pan et al.
ACS CENTRAL SCIENCE (2017)
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
T. Lee Collier et al.
MOLECULAR IMAGING (2017)
The role of the ALK receptor in cancer biology
B. Hallberg et al.
ANNALS OF ONCOLOGY (2016)
The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors
Dayong Zhai et al.
CANCER RESEARCH (2016)
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang et al.
CLINICAL CANCER RESEARCH (2016)
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins et al.
CLINICAL CANCER RESEARCH (2016)
Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)
Chih-Hsiang Tu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation
Dan-Dan Wang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Joachim T. Siaw et al.
ONCOTARGET (2016)
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Sean Khozin et al.
CLINICAL CANCER RESEARCH (2015)
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2015)
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation
John M. Hatcher et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer
Zhong Ni et al.
JOURNAL OF MOLECULAR MODELING (2015)
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Helen Y. Zou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
A novel lead compound CM-118 Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers
Lanfang Meng et al.
CANCER BIOLOGY & THERAPY (2014)
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Tatsushi Kodama et al.
CANCER LETTERS (2014)
ALK inhibitors in the treatment of advanced NSCLC
Cesare Gridelli et al.
CANCER TREATMENT REVIEWS (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
Dickran Kazandjian et al.
ONCOLOGIST (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib for the treatment of non-small-cell lung cancer
Andrew Timm et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2013)
Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment
Chi Hoon Park et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor
Jianyong Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Teeara Berry et al.
CANCER CELL (2012)
Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors
Marian C. Bryan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells
C. Schonerr et al.
ONCOGENE (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
Kazutomo Kinoshita et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
Roberto T. Bossi et al.
BIOCHEMISTRY (2010)
ALK Gene Rearrangements A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Benjamin Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase
Carmen J. Tartari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells
H Ruchatz et al.
EXPERIMENTAL HEMATOLOGY (2003)
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
WG Dirks et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
RY Bai et al.
BLOOD (2000)
分享论文
